Technology ID
TAB-3296
The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays
E-Numbers
E-563-2013-0
Lead Inventor
Shu, Bo (CDC)
Co-Inventors
Lindstrom, Stephen (CDC)
Wu, Kai-Hui (CDC)
Berman, LaShondra (CDC)
Emery, Shannon (CDC)
Warnes, Christine (CDC)
Applications
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Research Products
Research Equipment
Lead IC
CDC
ICs
CDC
CDC researchers have developed probes and primers for detecting the 2009 pandemic influenza A H1N1 virus in patient samples using real-time reverse transcription-polymerase chain reaction (rRT-PCR) methods. These primers and probes were originally developed in 2009 and were cleared by the FDA as part of a domestic human diagnostic testing panel in June 2010. These were also updated to increase specificity and/or sensitivity of the detection methods. The compositions and methods can be used to quickly identify 2009 pandemic influenza A (pdm InfA) and pandemic H1 (pdm H1), other influenza A virus sub-types (e.g., H3, H5, H7, and H9) and influenza B virus sub-types present in a sample. The CDC-developed probes and primers permit the rapid detection and/or discrimination of influenza virus subtype nucleic acids in initial clinical sample testing.
Commercial Applications
- Influenza A & pandemic influenza diagnostics using clinical specimens
- Government and regional influenza surveillance programs
- Quality control/quality assurance testing for influenza vaccine candidates
Competitive Advantages
- Assay allows for rapid universal detection and characterization of the 2009 A H1N1 pandemic influenza virus
- High sensitivity and specificity
- High-throughput sample screening and easily formatted as a kit or array
- Faster than culturing and serological identification methods
- Less laborious and more objective (quantitative) than immunoassays
Licensing Contact: